Lupin has received approval from the United States Food and Drug Administration (USFDA) for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg to market a generic version of Sunovion Pharmaceuticals, Inc's Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
Lupin's Lurasidone Hydrochloride Tablets is indicated for the treatment of adult patients with schizophrenia, monotherapy treatment of adult patients with major depressive episode associated with bipolar I disorder and adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated bipolar I disorder (bipolar depression).
Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg had annual sales of approximately $3217.3 million in the US (IQVIA MAT September 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
